Alpha radiation seeds target tumors from the inside

NCT ID NCT04534127

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a device called DaRT that delivers a unique type of radiation (alpha particles) directly into tumors. It is designed for people with certain skin cancers, mouth cancers, or soft tissue sarcomas that are accessible for direct injection. The goal is to see if this approach can shrink or control tumors while being safe.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Diffusing Alpha Radiation Emitters Therapy (DaRT) device
What this could lead to
If effective, this approach could offer a new, targeted treatment option for certain skin, mouth, and soft tissue cancers without the need for surgery or systemic therapy.
What could go wrong
This is an early study with a small number of participants, so results may not apply to all patients. The treatment involves inserting radioactive seeds into tumors, which carries risks like infection, pain, or incomplete tumor coverage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOSAL NEOPLASM OF ORAL CAVITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sharett institute, Hadassah Medical Center - Ein-Kerem

    RECRUITING

    Jerusalem, 91120, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.